Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.42 |
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | CLK3 | P49761 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.42 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373145 | 0.90 | CHRNA7 (0.50) | DYRK1AGSK3BCLK2CLK3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL1542509 | 0.83 | CHRNA7 (0.48) | DYRK1AGSK3BCHRNA7WNT1HTR3A | |
| Trifluoroacetic Acid SCHEMBL5407597 | 0.77 | CHRNA7 (0.53) | CHRNA7LSS | |
| SCHEMBL1542300 | 0.76 | CHRNA7 (0.41) | CHRNA7LSS | |
| Fumaric Acid SCHEMBL1542012 | 0.75 | CHRNA7 (0.58) | DYRK1AGSK3BCLK2CLK3CHRNA7 | |
| Fumaric Acid SCHEMBL1542011 | 0.75 | CHRNA7 (0.58) | DYRK1AGSK3BCLK2CLK3CHRNA7 | |
| Fumaric Acid SCHEMBL1542010 | 0.75 | CHRNA7 (0.58) | DYRK1AGSK3BCLK2CLK3CHRNA7 | |
| SCHEMBL1542398 | 0.74 | CHRNA7 (0.68) | DYRK1AGSK3BCHRNA7WNT1HTR3A | |
| SCHEMBL1542401 | 0.74 | CHRNA7 (0.68) | DYRK1AGSK3BCHRNA7WNT1HTR3A | |
| Trifluoroacetic Acid SCHEMBL1542269 | 0.73 | PIK3CA (0.43) | CHRNA7LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7674794-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-03-09 | — | — | US | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
| US-7160876-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | PRKAG1 1201/4885PRKAA1 1452/4885PRKAB1 1437/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | PRKAG1 2850/4885PRKAA1 2562/4885PRKAB1 2757/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | PRKAG1 1201/4885PRKAA1 1452/4885PRKAB1 1437/4885 |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | PRKAG1 1157/4885PRKAA1 1219/4885PRKAB1 1426/4885 |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | PRKAG1 1157/4885PRKAA1 1219/4885PRKAB1 1426/4885 |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | CHRNA7, CHRNA6, CHRNA10 | PRKAG1 1051/4885PRKAA1 1072/4885PRKAB1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.